Answers are grounded in this paper and cite their sources.
Reveals α2 receptor activation alters psychedelic effects of MDMA and psilocybin in mice, suggesting new therapy insights.
Classic serotonergic psychedelics such as psilocybin act as agonists at cortical serotonin (5-HT) 2A receptors (5-HT 2A R), inducing psychedelic effects in humans and head-twitch responses (HTRs) in rodents. Another class of psychedelic drugs called entactogens, exemplified by MDMA, function primarily as monoamine releasers and typically evoke minimal HTR despite causing serotonin release. The polypharmacology of psychedelic drugs at receptors other than 5-HT 2A R may modulate their behavioral effects. Here, we report that MDMA, but not psilocybin, induces robust elevations of both 5-HT and norepinephrine (NE) in the medial prefrontal cortex. Blocking the release of extracellular NE unmasks MDMA-evoked HTR, suggesting that polypharmacology involving noradrenergic receptors may oppose the 5-HT 2A –mediated effects of MDMA. Artificially elevating NE also attenuates psilocybin-induced HTR, supporting this hypothesis. Selective agonism of the noradrenergic α 2 receptor (α 2 R) is sufficient to suppress 5-HT 2A -mediated HTR, and also suppresses the HTR in locus coeruleus-ablated mice, suggesting that this effect is mediated by heteroreceptors. Moreover, psilocybin-induced effects in the forced swim test persisted in the presence of α₂R activation. Thus, these findings support a model in which some forms of 5-HT 2A signaling can be attenuated by α 2 R activation without interfering with antidepressant-like effects. The ability to reduce potential side effects of 5-HT 2A activation while preserving antidepressant-like effects via α 2 R and other analogous receptors may be relevant to therapeutic development.
No takes yet. Share an insight, caveat, or question.
Rosado et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: